GB2199243A - Pharmaceutical compositions comprising ornithine and arginine - Google Patents
Pharmaceutical compositions comprising ornithine and arginine Download PDFInfo
- Publication number
- GB2199243A GB2199243A GB08622417A GB8622417A GB2199243A GB 2199243 A GB2199243 A GB 2199243A GB 08622417 A GB08622417 A GB 08622417A GB 8622417 A GB8622417 A GB 8622417A GB 2199243 A GB2199243 A GB 2199243A
- Authority
- GB
- United Kingdom
- Prior art keywords
- composition
- components
- range
- present
- tyrosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
Abstract
A chemical composition consisting mainly of L-arginine and L-ornithine, possibly with a small admixture of at least one other component, is used for slimming, possibly in conjunction with L-tyrosine. One or more of the amino acids may be replaced by an equivalent.
Description
TITLE "AMINO ACID ETC, COMPOSITIONS"
BACKGROUND
(as herein defined)
This invention relates to amino acid and equivalent/compositions.
In this specification, the term "amino acid" is confined to those amino acids naturally occurring in food essential to the human body, of which 22 are known. They are the constituents of proteins, (which can be hydrolysed to produce the free form amino acids.) It is conceivable that there may be substances having molecules not identical with these acids but closely resembling them and having substantially equivalent effect in the human body. Such a substance is intended
an herein by reference to an "equivalent as herein defined" of/amino acid.
Such an equivalent of an amino acid may be transformed into the latter in the human body but is only within this definition if it does not act inconsistently with the principles hereinafter described.
The amino acid L-arginine has an important role in human metabolic processes. It is converted into L-ornithine in the human body, which stimulates the pituitary gland in the brain. This in turn releases the growth hormone somatotropih, which actually producers (a) an anabolic effect (it builds muscle protein) and (b) a catabolic effect (it mobilise fat).
L-ornithine is present in the body but only in configuration with all the other amino acids and therefore has only a limited effect. If large does are given of free form L-ornithine, it does appear to have slight effect on human metabolism. Dosing with L-arginine alpne also gives a slight increase in its action but this is still very limited.
THE INVENTION
However, the inventor has found that a combination of L-arginine and L-ornithine gives a much more enhanced metabolic effect, i.e. (a) and (b) mentioned above, far more than would have been expected on theoretical grounds considering either one alone. The overall effect appears to be a reduction in obesity, or 11slimming".
According to one aspect of the invention there is provided a chemical composition consisting substantially of the components L-arginine and l-ornithine, preferably with either one present in a range from 20% to 80%, more preferably 40% to 60%,and more preferably substantially 50% or equal proportions. Proportions given herein are weight in weight. While it is believed that a composition, to act usefully in accordance with the principles discovered by the inventor, has to consist preponderantly of these two ingredients, it is considered that (according to another aspect of the invention) small admixtures of at least one other ingredient possibly up to a proportion of 5% or 10% of the whole, may produce enhancement of one or both of the metabolic effects (a) and (b) or other advantages.
According to yet another aspect of the invention, there is provided a modification of the chemical composition just described in that part or all of one or of both of the amino acid constituents is replaced by an equivalent as herein defined. It is further considered that there is no essential distinction between a composition consisting of the two amino acids in physical mixture and a composition consisting of the two amino acids chemically attached to each other, as each is a stable entity and recognisable as such by the body.
The extra activity of the L-arginine appears to be that of a precursor for establishing the metabolic pathways triggering the conversion of
L-arginine to L-ornithine in the body, through some agency not properly understood, but enhancing their action on the pituitary gland.
EXAMPLES
In a trial, there were 12 subjects, each female and in the age range approximately 30 to 60 years and each suffering from considerable obesity. The composition was substantially equal proportions of L-arginine and L-ornithine mixed together and encapsulated, each capsule weighing about 8 gramme. The trial lasted about 2 months and each subject was given sufficient capsules to take one dose of four capsules each evening for a month and then given another supply for the second month. The recommended dosing conditions were with the stomach empty (or well after the evening meal) and just before going to bed.This was considered to give the best chances of the composition reaching the pituitary gland (rather than being lost in large quantities of food being digested at the same time) and to have the greatest effect on the pituitary gland to release the growth hormone somatotropin during sleep. Each subject was weighted at the beginning and end of each month and also underwent standard skin fold measurements at four sites to estimate total body fat content.
The subjects ranged from 55 to 75 kilogrammes in weight and each one lost between 3 and 6 kilogrammes over the period with a steady reduction of total body fat content amounting to around 5% at the end of the period and appearing to be a continuing loss rather than stabilising at a particular lower level. One subject was over the 75 kilogramme weight initially and it was considered that, above the range 55 to 75 kilogrammes, the dosage could usefully be increased from 2 grammes per dose to 3 grammes. It was particularly interesting to note that no subject was unaffected by the test All of the subjects were required to maintain their normal living style and diets throughout the trial.
It is considered that, while the desired effects could be obtained by putting the respective constituents into separate capsules and ensuring that doses consist of for example "two red and two blue capsules", there is less likelihood of mistakes and the procedure is much easier if all the capsules are identical
Further, it is considered that, while oral administration is easter and usually preferable, administration by other means,e.g.
directly into the blood stream, should still produce the desired effects and might in some cases be preferable.
Experiments have tended to show that the "slimming" (reduction in obesity) can be substantially improved by associating the composition described above with an appetite depressant. It is considered that the depressant most compatible with the said composition is another free form amino acid, L-tyrosine, preferably given in morning doses of 500 mgm. after each evening two gramme dose of the said trial, which provides a background level and starts to have a noticeable effect after about one week. According to anotht aspect of the invention, there is provided a pack comprising daily doses of the said composition and distinct therefrom (Iaily)doses of
L-tyrosine, which latter may be encapsulated, may be half the corresponding dose of the aforesaid composition and are preferably in the range of from half gramme to two grammes each, preferably one gramme.
All the amino acids used were obtained from Ajinomoto Company Ine of Japan.
Other aspects of the invention and features of embodiments appear from the appended claims, the disclosure of which is hereby imported into the present description.
Claims (37)
1. A chemical composition consisting substantially of the components L-arginine and L-ornithine.
2. A composition as claimed in claim 1, in which either of the said components is present in a range of from 20% to 80% w/w.
3. A composition as claimed in claim 1, in which either of the said components is present in a range of from 40% to 60% w/w.
4. A composition as claimed in claim 1, in which the said components are present in substantially equal proportions w/w.
5. A chemical composition consisting preponderantly of
L-arginine and L-ornithine with a small admixture of at least one other component.
6. A composition as claimed in claim 5, in which the admixture is present in a range of up to substantially 10% w/w.
7. A composition as claimed in claim 5, in which the admixture is present in a range of up to 5% w/w.
8. A composition as claimed in any one of claims 5 to 7, in which either of the said preponderant components is present in a range of from 20% to 80% w/w.
9. A composition as claimed in any one of claims 5 to 7,
either of in which/the said preponderant components is present in a range of from 40% to 60% w/w.
10. A composition as claimed in any one of claims 5 to 7, in which the said preponderant components are present in substantially equal proportions w/w.
11. A composition being a modification of a composition as claimed in any preceding claim, in which one or more of the components is partly or completely replaced by an equivalent as herein defined.
12. A pharmaceutical or dietary composition, comprising as active components L-arginine and L-ornithine.
13. A composition as claimed in claim 12, in which either of the said components is present in a range of from 20% to 80% w/w.
14. A composition as claimed in claim 12, in which either of the said components is present in a range of from 40% to 60% w/w.
15. A composition as claimed in claim 12, in which the said components are present in substantially equal proportions w/w.
16. A composition as claimed in any one of claims 12 to 15, comprising a small admixture of at least one other component.
17. A composition as claimed in claim 16, in which the admixture is present in a range of up to 107. w/w.
18. A composition as claimed in claim 16, in which the admixture is present in a range of up to 5% w/w.
19. A composition as claimed in any one of claims 12 to 18, in which one or more of the components is'partly or completely replaced by an equivalent as herein defined.
20. A pharmaceutical or dietary composition in unit dosage form, each unit consisting of a quantity in a range of from t to 1 gramme of a composition as claimed in any preceding claim.
21. A composition as claimed in claim 20, in which the said unit dosage quantity is substantially 8 gramme.
22. A composition as claimed in claim 20 or 21, in which each unit dosage quantity is encapsulated.
23, A pack comprising doses of a composition as claimed in any preceding claim, and distinct therefrom doses of L-tyrosine.
24. A pack as claimed in claim 23, in which both of the doses are daily doses.
25. A pack as claimed in claim 23 or 24, in which the doses of L-tyrosine are substantially half the weight of the other doses.
26. A pack as claimed in claim 23, 24 or 25, in which the doses of L-tyrosine are in a range of from substantially i gramme to substantially 2 grammes.
27. A pack as claimed in claim 23, 24 or 25, in which the doses of L-tyrosine are substantially 1 gramme.
28. The use of L-arginine and L-ornithine in combination in the manufacture of a composition for use in slimming.
29. A method of slimming comprising administering an effective amount of a composition as claimed in any one of claims 1 to 22.
30. A method as claimed in claim 29, in which said effective amount is in a range of from substantially 2 grammes per 55 kilograms body weight to substantially 2 grammes per 75 kilogrammes body weight daily.
31. A method as claimed in claim 29 or 30, in which the administration is done in the evening before sleep and not after a recent heavy meal.
32. A method as claimed in any one of claims 29 to 31, further comprising administering an effective amount of L-tyrosine.
33. A method as claimed in claim 32, in which said effective amount of L-tyrosine is substantially half the effective amount of th said composition.
34. A method as claimed in claim 32 or 33, in which the said effective amount of L-tyrosine is in a range of from substantially gramme to substantially 2 grammes daily.
35. A method as claimed in claim 32 or 33, in which the said effective amount of L-tyrosine is substantially 1 gramme daily.
36. A method as claimed in any one of claims 32 to 35, in which the administration of L-tyrosine is done in the morning after sleeping.
37. A composition, pack or method of slimming, substantially according to any embodiment or combination of embodiments hereinbeforf described.
37. A composition, pack or method of slimming, substantially according to any embodiment or combination of embodiments hereinbefor described.
Amendments to the claims have been filed as follows
CLAIMS
1. A slimming composition consisting substantially of the components L-arginine and L-ornithine.
2. A slimming composition consisting substantially of the components L-arginine and L-ornithine apart from unrelated components such as e.g. vehicles, binders, excipients and incidental components (e.g. sources of minerals and vitamins).
3. A composition as claimed in claim 1 or 2, in which the proportion of either one of the components L-arginine and
L-ornithine to the other is in a range between 4060 and 50-50 w/w.
4. A composition as claimed in claim 1 or 2, in which the said components are present in substantially equal proportions w/w.
5. A slimming composition consisting preponderantly of
L-arginine and L-ornithine.
6. A composition as claimed in claim 5, with a small admixture of at least one other component effective for slimming.
7. A composition as claimed in claim 6, in which the admixture is present in a range of up to substantially 10% w/w.
8. A composition as claimed in claim 7, in which the admixture is present in a range of up to 5% w/w.
9. A composition as claimed in any one of claims 5 to 7, in which the proportion of either one of the said preponderant components to the other is in a range between 40-60 and 50 50 w/w.
10. A composition as claimed in any one of claims 5 to 7, in which the said preponderant components are present in substantially equal proportions w/w.
11. A composition being a modification of a composition as claimed in any preceding claim, in which one or more of the components is partly or completely replaced by an equivalent as herein defined.
12. A slimming composition, comprising as active components
L-arginine and L ornithine.
13. A composition as claimed in claim 12, in which either of the said components is present in a range of from 20% to 60% w/w.
14. A composition as claimed in claim 12, in which either of the said components is present in a range of from 40% to 60% w/w.
15. A composition as claimed in claim 12, in which the said components are present in substantially equal proportions w/w.
16. A composition as claimed in any one of claims 12 to 15, comprising a small admixture of at least one other component.
17. A composition as claimed in claim 16, in which the admixture is present in a range of up to 10% w/w.
18. A composition as claimed in claim 16, in which the admixture is present in a range of up to 5% w/w.
19. A composition as claimed in any one of claims 12 to 18, in which one or more of the components is partly or completely replaced by an equivalent as herein defined.
20. A slimming composition in unit dosage form, each unit consisting of a quantity in a range of from k to 1 gramme of a composition as claimed in any preceding claim.
21. A composition as claimed in claim 20, in which the said unit dosage quantity is substantially 5 gramme.
22. A composition as claimed in claim 20 or 21, in which each unit dosage quantity is encapsulated.
23. A pack comprising doses of a composition as claimed in any preceding claim, and distinct therefrom doses of L-tyrosine.
24. A pack as claimed in claim 23, in which both of the doses are daily doses.
25. A pack as claimed in claim 23 or 24, in which the doses of L-tyrosine are substantially half the weight of the other doses.
26. A pack as claimed in claim 23, 24 or 25, in which the doses of L-tyrosine are in a range of from substantially s gramme to substantially 2 gramnes.
27. A pack as claimed in claim 23, 24 or 25, in which the doses of L-tyrosine are substantially 1 gramme.
28. The use of L-arginine and L-ornithine in combination in the manufacture of a composition for use in slimming.
29. A method of slimming comprising administering an effective amount of a composition as claimed in any one of claims 1 to 22.
30. A method as claimed in claim 29, in which said effective amount is in a range of from substantially 2 grammes per 55 kilogramn body weight to substantially 2 grammes per 75 kilogrammes body weight daily.
31. A method as claimed in claim 29 or 30, in which the administration is done in the evening before sleep and not after a recent heavy meal.
32. A method as claimed in any one of claims 29 to 31, further comprising administering an effective amount of L-tyrosine.
33. A method as claimed in claim 32, in which said effective amount of L-tyrosine is substantially half the effective amount of tl said composition.
34. A method as claimed in claim 32 or 33, in which the said effective amount of L-tyrosine is in a range of from substantially i gramme to substantially 2 grammes daily.
35. A method as claimed in claim 32 or 33, in which the said effective amount of L-tyrosine is substantially 1 gramme daily.
36. A method as claimed in any one of claims 32 to 35, in which the administration of L-tyrosine is done in the morning after sleeping.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08622417A GB2199243A (en) | 1986-09-17 | 1986-09-17 | Pharmaceutical compositions comprising ornithine and arginine |
| EP19870906193 EP0506653A1 (en) | 1986-09-17 | 1987-09-17 | Amino acid composition |
| PCT/GB1987/000648 WO1988001865A1 (en) | 1986-09-17 | 1987-09-17 | Amino acid composition |
| AU79691/87A AU7969187A (en) | 1986-09-17 | 1987-09-17 | Amino acid composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08622417A GB2199243A (en) | 1986-09-17 | 1986-09-17 | Pharmaceutical compositions comprising ornithine and arginine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB8622417D0 GB8622417D0 (en) | 1986-10-22 |
| GB2199243A true GB2199243A (en) | 1988-07-06 |
Family
ID=10604341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB08622417A Withdrawn GB2199243A (en) | 1986-09-17 | 1986-09-17 | Pharmaceutical compositions comprising ornithine and arginine |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0506653A1 (en) |
| AU (1) | AU7969187A (en) |
| GB (1) | GB2199243A (en) |
| WO (1) | WO1988001865A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1060739A1 (en) * | 1999-06-16 | 2000-12-20 | Exsymol S.A.M. | Slimming cosmetic composition containing L-arginine or a derivative thereof |
| FR2987270A1 (en) * | 2012-02-29 | 2013-08-30 | Agronomique Inst Nat Rech | COMBINATION PRODUCT FOR TREATING OVERWEIGHT AND / OR IMPROVING SILHOUETTE |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2745498A1 (en) * | 1996-02-29 | 1997-09-05 | Giroux Jean Marc | Composition to treat obesity, improves renal tolerance and rate of weight loss |
| US8968799B2 (en) * | 2006-09-01 | 2015-03-03 | Rise-N-Shine L.L.C. | Time delayed release mechanism for energizing composition and method of use |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1253830A (en) * | 1967-11-18 | 1971-11-17 | Yamanouchi Pharma Co Ltd | Method of preparing injections |
| GB1310658A (en) * | 1970-10-15 | 1973-03-21 | Richardson Merrell Spa | Composition and method for treatment of hepatic disease and mental fatugue |
| GB1507951A (en) * | 1975-02-03 | 1978-04-19 | Massachusetts Gen Hospital | Amino acid formulations |
| EP0059775A2 (en) * | 1980-06-09 | 1982-09-15 | Leopold & Co. Chem. pharm. Fabrik Gesellschaft m.b.H. | Infusion solution for the protection of the liver and the improvement of its functioning, and process for its production |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR958M (en) * | 1961-01-18 | 1961-11-27 | ||
| FR926M (en) * | 1961-01-18 | 1961-11-13 | ||
| US3867539A (en) * | 1973-04-27 | 1975-02-18 | Us Health | Method of producing anorexia as a treatment for obesity |
-
1986
- 1986-09-17 GB GB08622417A patent/GB2199243A/en not_active Withdrawn
-
1987
- 1987-09-17 EP EP19870906193 patent/EP0506653A1/en not_active Withdrawn
- 1987-09-17 AU AU79691/87A patent/AU7969187A/en not_active Abandoned
- 1987-09-17 WO PCT/GB1987/000648 patent/WO1988001865A1/en not_active Application Discontinuation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1253830A (en) * | 1967-11-18 | 1971-11-17 | Yamanouchi Pharma Co Ltd | Method of preparing injections |
| GB1310658A (en) * | 1970-10-15 | 1973-03-21 | Richardson Merrell Spa | Composition and method for treatment of hepatic disease and mental fatugue |
| GB1507951A (en) * | 1975-02-03 | 1978-04-19 | Massachusetts Gen Hospital | Amino acid formulations |
| EP0059775A2 (en) * | 1980-06-09 | 1982-09-15 | Leopold & Co. Chem. pharm. Fabrik Gesellschaft m.b.H. | Infusion solution for the protection of the liver and the improvement of its functioning, and process for its production |
Non-Patent Citations (1)
| Title |
|---|
| WO A1 85/00517 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1060739A1 (en) * | 1999-06-16 | 2000-12-20 | Exsymol S.A.M. | Slimming cosmetic composition containing L-arginine or a derivative thereof |
| FR2794974A1 (en) * | 1999-06-16 | 2000-12-22 | Exsymol Sa | COSMETIC COMPOSITION FOR L-ARGININE-BASED SLIMMING OF AN ANALOGUE OF L-ARGININE OR ONE OF THEIR DERIVATIVES, WHICH CAN BE APPLIED TOPICLY |
| US6716436B1 (en) | 1999-06-16 | 2004-04-06 | Exsymol S.A.M. | Cosmetic composition for slimming containing L-arginine, an L-arginine analogue, or one of their derivatives, for topical application |
| FR2987270A1 (en) * | 2012-02-29 | 2013-08-30 | Agronomique Inst Nat Rech | COMBINATION PRODUCT FOR TREATING OVERWEIGHT AND / OR IMPROVING SILHOUETTE |
| WO2013128137A1 (en) * | 2012-02-29 | 2013-09-06 | Institut National De La Recherche Agronomique - Inra | Combination product for treating excess weight and/or for improving the figure |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1988001865A1 (en) | 1988-03-24 |
| AU7969187A (en) | 1988-04-07 |
| GB8622417D0 (en) | 1986-10-22 |
| EP0506653A1 (en) | 1992-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SHAHIDI et al. | Testosterone-induced remission in aplastic anemia | |
| EP1176880B1 (en) | Supplement for restoring growth hormone levels | |
| KR0145739B1 (en) | Effervescent tablet | |
| TWI663970B (en) | Compositions for increasing human growth hormone levels | |
| JPS6339821A (en) | Remedy for articulation | |
| TW201417808A (en) | Methods for increasing endurance and fat metabolism in humans | |
| US9238024B2 (en) | Methods for improving health in canines | |
| TW201417809A (en) | Methods for increasing human growth hormone levels | |
| TW201424730A (en) | Methods for improving health in humans | |
| WO2014047314A1 (en) | Methods for improving thyroid function in healthy humans | |
| TW201424728A (en) | Compositions and methods for increasing human growth hormone levels | |
| US20100074968A1 (en) | Agent and method for treating cancer comprising strontium, amino acid(s) and mineral agent(s) | |
| Ingenbleek et al. | Thyroxine-binding globulin in infant protein-calorie malnutrition | |
| GB2199243A (en) | Pharmaceutical compositions comprising ornithine and arginine | |
| JP3137273B2 (en) | Compositions effective for diabetes | |
| JP2004256513A (en) | Agent for increasing amount of muscle | |
| Drop et al. | Hyperbilirubinaemia and idiopathic hypopituitarism in the newborn period | |
| CN113645966A (en) | Dosing regimen for orally absorbed highly soluble T4 thyroid hormone solution | |
| KR20040100835A (en) | Stabilized pharmaceutical and thyroid hormone compositions and method of preparation | |
| RU2220712C1 (en) | Agent and set for normalization of functional disorders arising in preclimacteric and climacteric period | |
| AU643073B2 (en) | Treatment of human lactation failure | |
| CN106075411A (en) | A kind of preparation method of natural iron supplement soft capsule | |
| GB2078516A (en) | Pharmaceutical compositions containing arginine and lysine | |
| US4576932A (en) | Dietary supplement and method | |
| JPS5962528A (en) | Fatigue recoverying agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |